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Purpose: Anti-infectives are among the most com-
monly prescribed medications in pregnancy. However,
detailed information on the pharmacokinetics and
pharmacodynamics of these medications in pregnancy
is limited, leading to uncertainty among clinicians
regarding the tolerability and efficacy of treatments.
The purposes of this review were to highlight key
physiologic changes during pregnancy that influence
drug behavior, and to discuss areas of active research
related to anti-infective drugs in pregnancy.
Methods: A review of literature in PubMed was
performed for topics related to physiologic changes of
pregnancy, postcesarean surgical site infections, vaccines in
pregnancy, and intrauterine infections. The literature was
reviewed and pertinent sources were utilized for this article.
Findings: Physiologic changes during pregnancy may
impact drug disposition and efficacy. Cefazolin regimens
are the current prophylactic treatment of choice for
postcesarean surgical site infections. Vaccines are pro-
vided in pregnancy for both maternal and neonatal
benefit. Broad-spectrum antibiotics continue to be used
as first-line therapy for intrauterine infections.
Implications: Continued efforts to broaden the
knowledge base on anti-infective drug behavior in
pregnancy will result in increased therapeutic options
for this population. (Clin Ther. 2016;38:2006–2015)
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Few drugs used in pregnancy have been explicitly
approved by the US Food and Drug Administration
(FDA) for use specifically during pregnancy. Despite
this fact, nearly 60% of women take medications
during pregnancy in the United States.1 Studies have
found that pregnant women take an average of 2 to 5
medications throughout their pregnancy course.2 Over
the past 3 decades, antibiotics and vaccines have been
consistently found among the 20 medications most
commonly prescribed in the first trimester.2 The
widespread prescription of anti-infective medications
in pregnancy has brought more attention to the
relative paucity of tolerability and efficacy data in
pregnant women compared with other patient pop-
ulations. A study of health care providers’ pregnancy-
related medication inquiries to an academic,
university-based drug information center over a dec-
ade identified infectious diseases as one of the most
common indications for information requests.3 Nearly
1 in 7 inquiries to the drug information center was
related to anti-infective medications, with a primary
focus on drug tolerability.3Scan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
phone must have a QR Code reader installed.
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strate the tolerability and efficacy of new medications
prior to widespread use. However, women have histor-
ically been underrepresented in this process, with the
majority of testing occurring in men and animals. The
rationale that data related to drug performance in men
can be extrapolated to women has been challenged as
our understanding of sex-related differences has in-
creased. A study of intrasubject variability in bioequi-
valence trials revealed up to a 2- to 6-fold difference in
variability in women compared to men.4 In fact, 30%
of studies of bioequivalence would not have passed if
drug performance between the sexes had been
compared.4 Accumulating data on these differences
has led to calls for regulatory bodies such as the FDA
and Health Canada require pharmaceutical developers
to test new medications in the specific populations in
which they are intended for use.5
Few medications have been studied in pregnant
women during the drug-approval process, due to a
myriad of tolerability and legal concerns. As a result,
the development of tolerability data on drug use in
pregnancy often occurs through postmarketing sur-
veillance. In the interim, practitioners are left to
extrapolate the anticipated behavior of a drug if they
or the pregnant patient desires its use during gestation.
Pharmacokinetic data on medication behavior, in
particular, are sparse in the pregnant population,
and are even less common for newly approved
medications. In 2015, the FDA issued an updated
Pregnancy and Lactation Labeling Rule6 to improve
the content and format of tolerability information on
medications used in pregnancy. A major feature of the
updated Pregnancy and Lactation Labeling Rule was
to replace the pregnancy letter categories (A, B, C, D,
and X) with descriptions of medication risks.
Clinical dosing of medications in pregnancy is based
primarily on data from studies that have been performed
in men and nonpregnant women, and does not account
for the characteristics that make pregnant women a
unique population to treat. The physiologic changes of
pregnancy influence the behavior of most drugs during
this phase of life. An understanding of these physiologic
changes can help a practitioner to anticipate changes in
the pharmacologic behavior of a medication. In turn,
practitioners can modify drug dosing to elicit the desired
pharmacodynamic effects. In this article, we review the
physiologic changes of pregnancy that affect dosing of
all medications in pregnancy, with a focus specifically onSeptember 2016recent areas of interest related to anti-infective drug
selection or dosing in pregnancy. Our goal was to
provide readers with a practical understanding of con-
cepts that they can apply to their own practices and to
the care of pregnant women.MATERIALS AND METHODS
A search using PubMed was performed for articles
published from January 1980 to July 2016 on topics
related to physiologic changes during pregnancy,
postcesarean surgical site infections (SSIs), vaccines
in pregnancy, and intrauterine infections. The litera-
ture was reviewed and pertinent sources were utilized
for this article.RESULTS
Information from 46 articles from the PubMed search
was used in this review. These sources were selected
based upon pertinence to the selected topics with
prioritization of more recent publications.
Physiologic Changes During Pregnancy
Pharmacokinetics describes the body’s absorption,
distribution, metabolism, and elimination (ADME) of
a drug. Each part of this pathway can be affected by
numerous physiologic changes that the body under-
goes during pregnancy that may greatly affect dosing
regimens. Absorption of the drug into the systemic
circulation is dependent on the route of administration
(oral, subcutaneous, intramuscular, intravenous, in-
halation, transdermal, per vagina, or per rectum).
Altered drug behavior due to changes in maternal
physiology can influence drug bioavailability, which is
the proportion of administered drug that reaches the
systemic circulation in intact form. The oral route of
administration is one of the most common with drugs
taken during pregnancy, and the effects of drugs taken
orally might be affected by several factors, including
stomach pH, food, gut transit time, local gut metab-
olism, and uptake and efflux transport processes.
Medications taken orally undergo a first-pass effect,
consisting of metabolism by enzymes in the gastro-
intestinal lumen, gut flora, and liver. In the general
population, the amount of intact drug reaching the
systemic circulation after the first-pass effect is greatly
reduced. In the pregnant state, there is decreased
gastric acidity, which may increase the ionization of
weak acids and may affect absorption. Additionally,2007
Clinical Therapeuticsan increase in the orocecal transit time due to
decreased intestinal mobility, an effect of the endog-
enous hormone progesterone, increases absorption.7
Blood volume increases in pregnancy to 40% to
45% above that in the nonpregnant state after 32 to
34 weeks.8 Due to this change, hepatic blood flow is
increased to 1.8 L/min.9 This increased blood flow
additionally increases the first-pass effect on oral
medications. Due to the many variables that affect
the absorption of oral medications, there is a wide
variation in plasma levels thus leading to variable
clinical and adverse effects.
The distribution of a medication refers to the
reversible transfer of a drug from one location to
another within the body. The volume of distribution
(Vd ¼ total drug in body/plasma concentration of
drug), which is the theoretic volume necessary for
maintaining the total drug at the current plasma
concentration, is used as a measure of the extent of
the distribution of a drug. If a drug is highly bound to
tissue, the Vd will be very large. A large Vd means a
lower plasma concentration due to a fraction of the
drug localizing to target receptors within tissues
(extravascular space). In cases of loss of a large
amount of blood volume, as is typical for a delivery,
drugs with a large Vd are more likely to remain in the
body (greater extravascular distribution) than are
drugs with a small Vd (primarily intravascular). An
additional feature unique to pregnancy is transplacen-
tal transfer of medications to the fetal compartment
(fetus, amniotic fluid, gestational tissues). The passage
of a drug into the fetal compartment is reflected by a
larger Vd than that in the nonpregnant state, primarily
due to distribution into the amniotic fluid. An in-
creased Vd may modify the efficacy of anti-infectives
by decreasing drug at maternal target receptor sites
while increasing fetal exposure.
The distribution of a drug is dependent on several
factors, including the level of perfusion of tissue,
plasma protein binding to the drug, lipid solubility,
vascular permeability, and tissue binding. Many of
these factors are altered in pregnancy, often leading to
increased drug distribution. Additionally, pregnancy is
a state of hypoalbuminemia, which increases the free
fraction of drug and decreases drug at the receptor
site.8 The renal system also changes during pregnancy
with increased activity of the renin–angiotensin–
aldosterone system leading to increased water and
sodium retention. Plasma volume expands by 1200 to20081600 ml compared with that in the nonpregnant state,
beginning as early as 6 to 8 weeks’ gestation and
reaching a peak at 32 weeks, with a total volume of
4700 to 5200 ml.10 Several other changes to the
cardiovascular system contribute to increased blood
flow and perfusion of tissues. Cardiac output increases
by 30% to 50% through increases in both stroke
volume and heart rate, and regional blood flow is
altered to favor perfusion of the pelvic organs.11
Blood flow to the uterus, kidneys, skin, and
mammary glands increases in pregnancy, while
blood flow to muscles decreases.9 These changes
result in an increased Vd of most medications, with
a preferential exposure of reproductive organs to
the drug.
The metabolism of a drug describes the range of
biochemical modifications performed by specialized
enzymatic systems in order to facilitate the excretion
of a xenobiotic. There are 3 phases of metabolism:
phase 1, oxidation, reduction, and hydrolysis by
cytochrome P450 (CYP) enzymes and flavin mono-
oxygenases; phase 2, conjugation to polar compounds
with sulfate, glucuronic acid, glycine, or glutathione;
and phase 3, further metabolism and transport. The
activation of metabolic enzymes is highly variable and
is affected by a range of factors, such as race, ethnicity,
age, concurrent medications, and pregnancy. The elevated
hepatic blood flow in pregnancy of 1.8 L/min in-
creases the exposure of xenobiotics to the metabolic
enzymes, which promotes the first-pass metabolism of
drugs. CYP enzyme activity is also altered as a result
of the changing hormonal milieu of pregnancy, result-
ing in increased activity of some enzymes such as
CYP34A, -2C9, -2D9 and decreased activity of others
such as CYP1A2.11 A detailed understanding of the
enzymatic metabolism of a drug of interest is crucial
to anticipating increases or decreases in drug concen-
tration as a result of metabolism in pregnancy, and
hence altered dosing requirements to achieve pharma-
codynamics goals.
Elimination is the final step in the pathway of drugs
in the body; it is the process by which a drug is
excreted either in an unaltered form or after modifi-
cation into metabolites. Routes of elimination are
commonly through the kidney, liver, skin, lungs, feces,
and glands (breast, lacrimal, salivary, sweat). Alter-
ations in the elimination of a medication result in the
accumulation of the parent drug or its metabolites.
In pregnancy, the aforementioned cardiovascularVolume 38 Number 9
Table. Physiologic changes during pregnancy and their effects on drug pharmacokinetics (PK).
System Changes During Pregnancy Effects on PK
Cardiovascular Plasma volume expansion 1) Increased volume of distribution
2) Decreased concentration of drug at
the receptor site
Begins at 6–8 wk GA
Peaks at 32 wk (4700–5200 mL)
Increases 1200–1600 mL above that in
nonpregnant women
Cardiac output increase 30%–50% 1) Increased blood flow
2) Increased clearance of drug50% by 8 wk GA
Increases in SV and HR
SV in early pregnancy
HR in late pregnancy
Changes in regional blood flow
Increased to uterus, kidneys, skin, and mammary
glands
Decreased to skeletal muscle
Hepatic blood flow 1) Increased blood flow
2) Increased metabolism
3) Increased clearance of drug
Constant during pregnancy 1.8 L/min
Respiratory Decreased functional reserve capacity 1) Increased clearance of drug from lungs
2) Altered metabolism and systemic
clearance
Increased respirations
Lowered PaCO2
Compensated respiratory alkalosis
Metabolism Hypoalbuminemia 1) Decreased drug at receptor site
2) Decreased drug effectIncrease in free fraction of drugs bound to albumin
Enzymatic activity Altered metabolism of drugs
N-methylation inhibited by progesterone
P450 activity
Increases in 34A, 2C9, 2D6
Decrease in 1A2
Renal Blood flow increased 50% Increased clearance of drug
Decreased renal vascular resistance
GFR increased 50%
Reduction in serum creatinine and urea 1) Increased volume of distribution
2) Decreased concentration of drug at
receptor site
Increased activity of RAAS
Sodium and water retention
Gastrointestinal Decreased gastric acidity Altered absorption (K2)
(continued)
A.S. Patil et al.
September 2016 2009
Table. (continued).
System Changes During Pregnancy Effects on PK
Gastric emptying Delayed peak concentration
Delayed in laboring women
No difference between 1st and 3rd trimester in
nonlaboring women
No difference from postpartum
Increased orocecal transit time in 3rd trimester Increased absorption
Progesterone effect
Pancreatic polypeptide inverse correlation
GA ¼ gestational age; GFR, glomerular filtration rate; HR ¼ heart rate; RAAS ¼ renin–angiotensin–aldosterone system; SV ¼
stroke volume.
Clinical Therapeuticschanges, including increased cardiac output (increased
stroke volume and heart rate) and preferential re-
gional blood flow, contribute to the increased clear-
ance of a drug. Increased hepatic flood flow and renal
blood flow due to decreased renal vascular resistance
also contribute to enhanced elimination.12 Elimination
through the kidneys is the primary method of drug
disposition, although elimination may also occur
through the lungs. Pregnant women have increased
respirations and a decreased functional reserve
capacity, which lead to a lowered PaCO2 and thus a
compensated respiratory alkalosis.10 These factors
contribute to the increased clearance of inhalational
drugs from the lungs. Another important contributor
to elimination are drugs that are administered
concurrently. Drug–drug interactions, or metabolic
enzyme induction/inhibition, may affect the
elimination rate of the drug of interest. A summary
of physiologic changes of pregnancy is presented in
the Table.
Surgical Site Infections
SSIs are a common cause of morbidity in patients
who undergo any surgery, and cesarean sections are
no exception. In the population of patients who
undergo cesarean section, there are many risk factors
for infection. Standard of care dictates the use of
antibiotic prophylaxis, typically in the form of a single
dose of IV cefazolin at the initiation of surgery, to
decrease the risk for SSI.13 A Cochrane review on the
subject of prophylactic antibiotics at the time of2010cesarean section noted that the risk for endometritis
was reduced by 76% in a group who underwent
elective cesareans, and remained significant in a group
who underwent emergent cesareans.14 The most cost-
effective regimen appears to be a single dose of
cefazolin.13,15,16 The standard cefazolin dose in preg-
nant women is 1 g, although a higher dose (2 g) is
recommended for patients with a body mass index
(BMI) of Z30 kg/m2 or a weight of 4100 kg.13,17
As the pregnant population becomes increasingly
obese, doses of prophylactic antibiotics at the time of
cesarean delivery have come into question. Elkomy
et al18 assessed serum antibiotic levels after a 1-g cefazolin
dose in pregnant women undergoing cesarean deliv-
ery. Using the data collected, the investigators
created a pharmacokinetics model to assess cefazolin
clearance in pregnancy, and thus the adequacy of
dosing. The investigators concluded, based on their
modeling, that due to increased cefazolin clearance
in pregnancy, larger doses (than 1 g) were necessary
to obtain the antibiotic effect seen in nonpregnant
women. Pevzner et al19 assessed the adequacy of a
higher dose (2 g), comparing adipose and serum
cefazolin concentrations in 3 groups of 10 patients
with BMIs of o30 to 39.9, and 440 kg/m2. In that
population, a large percentage of patients in the
higher-BMI groups did not attain a tissue concen-
tration above the minimum inhibitory concentration
for gram-negative rods, suggesting that a dose 42 g
may be necessary in obese pregnant women. In a
second phase of that study, Swank et al20 gave 3 g ofVolume 38 Number 9
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same BMI categories, then compared the serum and
adipose levels. All of the patients in the higher-BMI
classes who received 3 g attained tissue concentra-
tions above the minimum inhibitory concentration.
Based on these data and the comparison to the 2-g
data, the investigators concluded that 2 g was an
adequate dose in normal and overweight patients,
while obese patients may need 3 g for adequate
prophylaxis. During the interim between the 2
previous studies, Stitely et al21 compared serum
and adipose levels after the administration of a
dose of 2 or 4 g of cefazolin for prophylaxis in
patients with a BMI 435 m2/kg. All of the patients
in both groups, independent of BMI, attained tissue
and serum levels above the minimum inhibitory
concentration, leaving the investigators unable to
conclude whether the higher dose was in fact
protective. In a more recent, randomized,
controlled trial, Maggio et al22 compared adipose
cefazolin levels in 57 patients receiving 2- or 3-g
doses. All of the samples had cefazolin levels above
the minimum inhibitory concentration. Thus, in that
trial, the authors concluded that the data were not
adequate to support the use of 3 g of cefazolin in the
obese population.
However, the previously mentioned studies all were
geared to assess tissue concentrations, not clinical
outcomes. In 2015, Ahmadzia et al23 conducted a
retrospective cohort study to do just that. That study
included 335 patients with a median weight of 140.6
kg, 175 of whom received a 2-g dose and 160 of
whom received a 3-g dose. The difference in SSIs
between the 2 groups was not significant. Thus, in
that clinical study, the investigators concluded that a
3-g dose of cefazolin did not significantly reduce SSIs.
Based on the above data, while it appears that a
single dose of a cephalosporin antibiotic is sufficient
for obtaining adequate tissue concentrations and
reducing SSI risk in most patients, a subset of patients
may benefit from higher doses of antibiotics. More
recently, the utility of dual-antibiotic regimens has
been investigated to further reduce the prevalence of
postcesarean infections. In particular, Ureaplasma and
Mycoplasma spp are components of polymicrobial
postcesarean infections that are not effectively treated
with cephalosporins. Researchers have examined azi-
thromycin as a secondary component of the antibiotic
prophylactic regimen, finding myometrial tissueSeptember 2016concentrations adequate for treating Ureaplasma spp
infections and efficacy in the prevention of endome-
tritis.24,25 Efforts continue to identify and address the
etiologies of postsurgical infections through the selec-
tion of effective antibiotics and stratification of dosing
regimens in patients at highest risk for inadequate
antibiotic tissue concentrations.
Vaccines
Pregnancy is a particularly vulnerable time for
women to contract viral and bacterial diseases due
to a general decrease in immunity, creating potential
harm to both the mother and fetus. In addition,
infants go unprotected during the first few months
of life due to their immature immune system and
inability to receive vaccines. Vaccination during preg-
nancy is an efficient way to offer protection to not
only the mother but also the fetus/infant. It has long
been established that immunoglobulin G antibodies
are actively transported through the placenta, provid-
ing antibodies to the fetus.26–28 This transplacental
transport increases with gestational age, with peak
transport occurring during the final 4 weeks of
gestation.28 Following delivery, these antibodies
remain in the infant, offering the potential for
passive immunity in the first months of life against
diseases associated with significant morbidity and
mortality.26,27 However, the levels of antibodies in
the fetus are directly related to the maternal levels, and
vaccinations during pregnancy can increase antibodies
in the fetus to levels adequate for protection.28 For
example, the recommended Tdap (tetanus, diphtheria,
and pertussis) vaccine is given during the third
trimester in an attempt to increase the levels when
transplacental transport is at its greatest, therefore
increasing the fetus’ antibody levels.28 In contrast, live
attenuated vaccines are contraindicated in pregnancy
due to the theoretic risk for transmission to the fetus,
although studies have not confirmed this risk.28–30
Currently, the only vaccines recommended in all
pregnant women are the seasonal influenza and Tdap
vaccines, which have not been associated with acute
adverse outcomes in patients who received both.31
Influenza during pregnancy has been associated
with a significant increase in poor outcomes, including
increased rates of maternal hospitalizations, pneumo-
nia, intensive care unit admissions, and mortality.32–34
Influenza also has been associated with increased rates
of pregnancy loss, stillbirth, neonatal death, preterm2011
Clinical Therapeuticsbirth, and low birth weight.29,30,32 To help prevent
these complications, the Centers for Disease Control
and Prevention and the American Congress of Ob-
stetricians and Gynecologists recommend that all
pregnant women receive the yearly influenza vaccine
regardless of gestational age.35 Studies have reported
that pregnant women who received the vaccine had a
lower risk for preterm birth or infants small for
gestational age, and a decreased risk for fetal
death.29,30,33 Additionally, vaccination has a longitu-
dinal impact beyond the prenatal period as a result of
trans-placental transfer of maternal antibodies to the
fetus. Infants cannot receive the influenza vaccine until
age 6 months, leaving them particularly vulnerable
during the first few months of life.29 Influenza is
particularly dangerous to infants: The rate of
hospitalization due to influenza is higher in infants
aged o6 months than in any other group.27,33 One
study reported a 63% reduction in infant influenza
and a 29% reduction in other febrile illnesses in
infants of mothers who received the influenza vaccine
during pregnancy.33 Maternal vaccination was found
to have a 91.5% likelihood of preventing infant
hospitalization due to influenza.27 The transplacental
passage of immunoglobulin G antibodies is thought to
be the key parameter explaining the success of
maternal immunization for neonatal benefit. While
the influenza vaccine offers significant benefits to
pregnancy, improved infant outcomes, especially in
pandemic years, can be of equal importance. While
educating patients on these benefits, it is important to
emphasize the maternal, fetal, and neonatal benefits.
Pertussis, more commonly known as whooping
cough and caused by the bacteria Bordetella pertussis,
is prevented by the DTap (diphtheria, tetanus, and
pertussis) vaccine in infancy and later the Tdap in
adolescence and adulthood. Pertussis is known to cause
significant morbidity and mortality in infants, with this
population being at the greatest risk.26,28,36 In fact,
newborns have rates of hospitalization and deaths
higher than those of any other population.37 This
finding is in part due to infants not being protected,
as they do not start their vaccinations until 2 months of
life, and immunity not appearing until 6 months.30,36
Although the prevalence of pertussis had been low for
many years, it increased significantly in 2012, prompt-
ing the Centers for Disease Control and Prevention to
recommend that all pregnant women be vaccinated
during the perinatal period, specifically in the third2012trimester.29,30,32 Vaccination during pregnancy pro-
vides protection to the mother, as well as passive
immunity to the infant, with antibodies remaining for
up to 6 weeks of life.26,32,36,37 A recent study from
Belgium reported that infants of women who received
vaccinations during the third trimester had significantly
higher antibody levels at 8 weeks of life compared with
infants of mothers who had no vaccine in the previous
10 years.26 The practice of perinatal vaccination for
pertussis has been widely implemented, and recent
research suggests that the vaccine may be 91%
effective in preventing pertussis in infants.36 Further
long-term studies are needed to assess the clinical
impact of maternal vaccination during the third
trimester on neonatal pertussis rates.
With the implementation of this vaccination strat-
egy, however, there is a residual concern that the
maternal antibodies may prevent the infant’s immune
system from appropriately responding to other immu-
nizations, potentially decreasing the child’s immunity
later in life. Infants of vaccinated mothers have been
reported to have lower levels of antibodies after the
third vaccine in the series compared with infants of
mothers who were not vaccinated, but no differences
in clinical outcomes were observed.26 The theory of
potentially decreasing immunity with the current
vaccination schedule is yet to be clinically proven,
and further studies are needed. In the meantime,
clinicians should weigh the potential benefit of
preventing a dangerous and high-risk infection in
infants against the theoretical risk for decreased
immunity with future immunizations.
Intrauterine Infections
Chorioamnionitis is present in an estimated 3% to
5% of all pregnancies.38 Although its diagnosis can be
defined both clinically and histologically, most
institutions use a modification of the Gibbs criteria,
which includes fever (4381C) and 1 or more of the
following: maternal or fetal tachycardia, fundal
tenderness, and/or foul-smelling, purulent vaginal
discharge. The most commonly offending pathogens
include Escherichia coli, group B streptococci,
Bacteroides spp, and anaerobes.39 This diverse
group of bacteria led practitioners to use broad-
spectrum antibiotics once the diagnosis had been
established. There was, however, no clear consensus
on whether to treat mothers intrapartum or postpar-
tum. An initial study by Gibbs et al40 reported thatVolume 38 Number 9
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broad-spectrum antibiotics was associated with de-
creased neonatal sepsis and improved neonatal and
maternal outcomes. The antibiotic regimen included
ampicillin 2 g IV q6h and gentamicin 1.5 mg/kg
IVq8h. While this provided new insight into the
management of chorioamnionitis, the ideal antibiotic
(s) and dosing regimen was still unknown. Ampicillin
and gentamicin had been historically used by most
physicians due to their extensive gram-positive and
gram-negative coverage. Gilstrap et al41 validated this
combination of antibiotics by comparing the cord
blood levels of five different antibiotics—
clindamycin, mezlocillin, ampicillin, cefoxitin, and
gentamicin—in patients with clinical chorio-
amnionitis. They reported that ampicillin and
gentamicin were associated with the highest cord
blood–to–maternal blood ratios. These studies led to
most institutions implementing a protocol of
administering ampicillin 2 g IVq6h and gentamicin
1.5 mg/kg IVq8h, with the addition of clindamycin
900 mg for anaerobic coverage prior to cesarean
delivery.42
In 2005, Locksmith et al43 delved further into
optimal gentamicin dosing and compared umbilical
cord and maternal peak gentamicin concentrations
between patients who received once-daily dosing
(5.1 mg/kg/d) compared with TID dosing (120 mg
followed by 80 mg q8h) for clinical chorioamnioni-
tis. Interestingly, once-daily dosing was associated
with fetal serum drug levels that were consistently
45 μg/mL, whereas conventional dosing led to
serum levels in the range of 2 to 4 μg/mL. Due to
concerns for kidney or 8th cranial nerve damage,
though, most physicians have continued to follow
conventional dosing. Surprisingly, there have been
few studies to date that have compared conventional
dosing to that of other broad-spectrum antibiotics.
Recently, attention has been turned to ertapenem as
an alternative to the conventional regimen of ampi-
cillin/gentamicin/clindamycin due to its character-
istics of a newer broad-spectrum agent requiring
only once-daily dosing. However, evidence of the
efficacy of ertapenem is conflicting and further
studies are needed.44,45 As bacterial resistance to
antibiotics continues to evolve and newer antibiotics
become available, there will be a need for additional
trials to determine antibiotic regimens appropriate
for the obstetric patient.September 2016DISCUSSION
Anti-infective medications are commonly utilized in
pregnant women despite limited formal testing of
tolerability and efficacy. Clinicians must be aware of
the physiologic changes during pregnancy that may
modify the anticipated behavior of an anti-infective
medication. These concepts can be used for rational
modification of dosing regimens to elicit optimal
pharmacodynamics effects. Current areas of interest
related to anti-infective medication use in pregnancy
include postcesarean infections, vaccines, and intra-
uterine infections. While not addressed in this article,
a critical evaluation of therapeutic options for infec-
tions during pregnancy (pyelonephritis, pneumonia)
may also result in dosing modifications to account for
physiologic changes. These are some of the areas in
which there are ongoing efforts to optimize drug
selection or dosing regimens to in turn optimize
clinical outcomes.
In the future, attention may be shifted to a
personalized medicine approach to therapeutic inter-
ventions in obstetrics.46 Specifically, research is
needed to characterize the contribution of genetic
polymorphisms in drug-metabolizing enzymes or
transport proteins on the pharmacokinetics of anti-
infective medications. The goals of these research
efforts should be to improve identification and to
optimize treatment in pregnant women at risk for
suboptimal outcomes. Pregnant women are a special,
understudied population that can benefit from con-
tinued efforts to improve anti-infective treatment
regimens.CONCLUSIONS
Physiologic changes during pregnancy may impact
drug disposition and efficacy. Cefazolin regimens are
the current prophylactic treatment of choice for
postcesarean SSIs. Vaccines are provided in pregnancy
for both maternal and neonatal benefit. Broad-
spectrum antibiotics continue to be used as first-line
therapy for intrauterine infections. Continued efforts
to broaden the knowledge base on anti-infective drug
behavior in pregnancy will result in increased ther-
apeutic options for this population.ACKNOWLEDGMENTS
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